Methylated SFRP1,2 and CD25 Expression in Acute Myeloid Leukemia Play an Important Role in the Pathogenesis of the Disease and in Turn in its Treatment
| Autor: | Azza A Abo Elfadle, Mohamed Z Abd Elrahman, Dalia Ahmad Nigm |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Acute myeloblastic leukemia business.industry Chronic lymphocytic leukemia Myeloid leukemia Methylation medicine.disease Pathogenesis 03 medical and health sciences Leukemia 030104 developmental biology 0302 clinical medicine hemic and lymphatic diseases 030220 oncology & carcinogenesis DNA methylation Immunology medicine Cancer research Hairy cell leukemia business neoplasms |
| Zdroj: | Journal of Leukemia. 4 |
| ISSN: | 2329-6917 |
| DOI: | 10.4172/2329-6917.1000219 |
| Popis: | Objectives: Recently, hyperactivation of the Wnt signaling pathway has been implicated in leukomogenesis, so we studied the epigenetic dysfunction of SFRP1,2 and expression of interleukin2 receptor α chain (IL2Rα, also known as CD25) and its prognostic impact in acute myeloblastic leukemia (AML). Methods: We studied the methylation profile of SFRP1,2 in AML cells by methylation-specific polymerase chain reaction (MSP) and the hyper expression of IL2Rα (CD25) by flowcytometry. Results: We analyzed the methylation profile of SFRP1,2 in 40 de novo AML patients. The percentage of hypermethylation in the patient samples were 37.5% for SFRP1, 12.5% for SFRP2. CD25 was positive in 12(30%) of 40 patients AML. We found that in patients whom 60 years and younger with intermediate risk cytogenetics in de novo AML, hypermethylation of SFRP1 and CD25 were accompanied with relapse (P=0.024). Conclusion: Our data indicates that in a subgroup of AML patients, hypermethylation of SFRP1 and high expression of CD25 predict relapse |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|